This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Haworth, R Articles by Pilling, A M Search for Related Content PubMed PubMed Citation Articles by Haworth, R Articles by Pilling, A M Social Bookmarking                         What's this?

The PCR assay in the preclinical safety evaluation of nucleic acid medicines

Molecular Pathology Group, Medicines Safety Evaluation Division, Glaxo Wellcome Research and Development Ltd., Park Road, Ware, Hertfordshire SG12 ODP, UK

A M Pilling

Molecular Pathology Group, Pathology Department, Medicines Safety Evaluation Division, Glaxo Wellcome Research and Development Ltd., Park Road, Ware, Herts SG12 ODP, UK

The polymerase chain reaction (PCR) is a highly efficient gene amplification procedure which is increasingly being applied to the safety assessment of nucleic acid (NA) medicines such as gene therapies and DNA vaccines.

Although clinical experience is limited, a number of potential safety issues exist with these new compounds including toxicity associated with the expression of encoded gene products, autoimmunity due to the induction of anti-DNA antibodies and insertional mutagenesis. PCR enables these questions to be addressed and provides data on mRNA expression, biodistribution and integration.

In this review the use of PCR methodologies in the preclinical safety evaluation of NA medicines is discussed. Particular consideration is given to the issues surrounding the use of PCR in regulatory toxicology, including sensitiv-ity requirements, cross-contamination problems, tissue sampling procedures and good laboratory practice (GLP) compliance. In addition, the use of a PCR-based assay to demonstrate the integration of DNA vector into host DNA is described.

As the use of PCR in the development of NA medicines will undoubtedly increase over the next few years, it is important that pathologists and toxicologists familiarise themselves with the principles and applications of this technique.

Key Words: polymerase chain reaction • nucleic acid medicines • integration

Human & Experimental Toxicology, Vol. 19, No. 5, 267-276 (2000)
DOI: 10.1191/096032700678815891


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Draghia-Akli, K. K. Cummings, A. S. Khan, P. A. Brown, and R. H. Carpenter Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs J Anim Sci, September 1, 2003; 81(9): 2301 - 2310. [Abstract] [Full Text] [PDF]